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Wild-type p53 is required for apoptosis induced by growth factor
deprivation in factor-dependent leukaemic cells
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Summary The p53 gene is a growth control gene, abnormalities of which have been implicated in a variety of
cancers. Recently wild-type p53 has been shown to exist in two interchangeable conformational variants,
which can be distinguished by specific p53 monoclonal antibodies. One conformation acts as a suppressor
(PAb240-/PAbl620+) and one acts as a promoter (PAb240+/PAbl620-) of cell proliferation; the latter
conformation is also that of mutant p53. We have previously shown that acute myeloblastic leukaemia (AML)
blasts which proliferate autonomously in vitro express only p53 in the promoter conformation. In contrast,
expression of PAb 1620 was found only in blasts with non-autocrine growth in vitro and was diminished
following stimulation by exogenous growth factors when there was a switch to p53 in the promoter
(PAb240+) conformation. As AML blasts with non-autocrine growth undergo apoptosis when deprived of
exogenous growth factors, we studied whether this was mediated by wild-type p53. Antisense oligonucleotides
to p53 were used to suppress p53 protein expression in blasts with non-autocrine growth and also the
factor-dependent human erythroleukaemia cell line TF-1. Following growth factor deprivation for 48 h,
20.6-53.6% of control blasts were apoptotic and demonstrated a typical 'ladder' on DNA electrophoresis
characteristic of internucleosomal degradation of DNA. In the presence of p53 antisense, apoptosis was
suppressed despite the absence of growth factor, however cell proliferation was not stimulated. We conclude
that apoptosis occurring in factor-dependent AML blasts following growth factor deprivation is mediated by
wild-type p53 (PAb 1620+), and that conformational change of p53 to the PAb240+ conformation occurring
either by mutation or by the action of autocrine growth factors would permit leukaemic cell survival by
suppressing apoptosis.
A number of regulatory genes which influence cellular
susceptibility to enter the physiological process of cell death
known as apoptosis have been identified, including c-myc
(Evan et al., 1992), bcl-2 (Hockenbery et al., 1990; Bissonette
et al., 1992) and p53. Wild-type p53 is classified as a tumour-
suppressor gene (Eliyahu et al., 1989; Finlay et al., 1989).
Introduction of wild-type p53 into cell lines that have lost
endogenous p53 function results in growth arrest (Baker et
al., 1990; Diller et al., 1990; Mercer et al., 1990) and apop-
tosis (Yonish-Rouach et al., 1991; Shaw et al., 1992).
Recently, further evidence has shown that wild-type p53 (but
not mutant p53) is required for radiation-induced apoptosis
in thymocytes (Lowe et al., 1993), and that p53 exerts a
significant and dose-dependent effect on apoptosis induced by
radiation and agents that cause DNA strand breakage, such
as chemotherapeutic drugs (Clarke et al., 1993). However,
other mechanisms which induce apoptosis have been de-
scribed, including the withdrawal of trophic factors (Arends
& Wyllie, 1991).
The viability and proliferation of leukaemia cells from
patients with acute myeloblastic leukaemia (AML) is depen-
dent upon the presence of haemopoietic growth factors
(Lowenberg & Touw, 1993). Unlike normal haemopoietic
progenitors, some myeloid leukaemia cells produce autocrine
growth factors (Young & Griffin, 1986; Reilly et al., 1989;
Russell, 1992). We have found that both autocrine and
exogenous granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) act to maintain viability and to suppress
apoptosis in blast cells from patients with AML. AML blasts
which do not produce autocrine GM-CSF rapidly lose
viability due to apoptosis when cultured without added
growth factors. Similar changes were observed in the factor-
dependent human erythroleukaemia cell line TF-1 following
growth factor deprivation (Bradbury et al., 1993). In con-
trast, leukaemic cells which produced autocrine GM-CSF
were found to be protected against apoptotic cell death fol-
lowing in vitro culture. Thus, normal haemopoietic pro-
genitor cells and growth factor-dependent myeloid leukaemia
cells undergo apoptosis following deprivation of haemo-
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poietic growth factors (Williams et al., 1990; Lotem et al.,
1991; Bradbury et al., 1993). As p53 has been shown to
promote apoptosis in leukaemic cells (Yonish-Rouach et al.,
1991), and as p53 protein has been shown to exist in different
conformations in AML blasts and to be regulated by exo-
genous and autocrine growth factors (Zhu et al., 1993), we
have investigated the role of wild-type p53 in mediating




Blood samples were obtained at diagnosis from four patients
with AML and peripheral blood blast count of >2 x 109 1-'.
The diagnosis of AML was made using FAB criteria follow-
ing conventional cytochemical stains and surface marker
analysis. Mononuclear cells were separated by Ficoll-
Hypaque sedimentation and samples were depleted of T cells
by Dynabeads M-450 Pan-T (CD2) (Dynal, Oslo, Norway).
Samples were cryopreserved in 10% dimethylsulphoxide
(DMSO) and 20% fetal calf serum (FCS) in liquid nitrogen.
Viability of thawed cells was greater than 90%. TF-I is a
human erythroleukaemia cell line (Kitamura et al., 1989),
which was kindly donated by T. Kitamura (DNAX Research
Institute of Molecular and Biology, Palo Alto, CA,
USA).
Antibodies and oligonucleotidesforp53
Three purified mouse monoclonal antibodies for p53 were
used (Oncogene Science, NY, USA). PAb 1801 recognises an
epitope between amino acids 32 and 79 (Banks et al., 1986).
PAb240 recognises an epitope between amino acids 156 and
335 (Gannon et al., 1990). PAb 1620 was developed by Ball et
al. (1984) and has been shown to recognise a conformational
epitope specific for wild-type p53 (Ball et al., 1984; Milner &
Medcalf, 1991).
Eighteen-mers of p53 oligonucleotides were obtained from
British Bio-technology (Oxford, UK). They correspond to the
sense or antisense sequences flanking the translation initia-
tion regions of the messenger RNA for p53 (Zakut-Houri et
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al., 1985). The sequence of the phosphorothioate oligo-
nucleotides with the ATG initiation codon or its complement
CAT in the sense and antisense sequence was as follows:
sense, 5'-ACTGCCATGGAGGAGCCG-3', antisense, 5'-
CGGCTCCTCCATGGCAGT-3'.
Western blotting
Cells (107) were washed with PBS (pH 7.2) twice, then lysed
for 15 min at 4°C with 300jil of lysis buffer [50 mM Tris-HCl
pH 8.0, 0.25 M sodium chloride, 0.1% Nonidet P-40, 50 mM
EDTA, 1 mM phenylmethylsulphonyl fluoride (PMSF),
50Sig ml-' aprotinin]. The lysates were collected by micro-
centrifugation for 10 min. Protein concentrations of the
lysates were determined by the method of Lowry et al.
(1951). Aliquots of 100 jig of each lysate were analysed by
7.5% SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
with the Laemmli buffer system (Laemmli, 1970). The gels
were run at 150 V for 45 min in a mini protein II slab cell
(Bio-Rad, Richmond, CA, USA). Proteins in the gel were
transferred onto nylon membrane by electrophoretic transfer
(0.8 mA cm-2 membrane, about 60 min) in a continuous
buffer system [39 mM glycine, 48 mM Tris, 0.0375% (w/v)
SDS, 20% (v/v) methanol]. Non-specific binding was blocked
by incubation of the membrane with 0.5% bovine serum
albumin (BSA) in TBST (0.01 M Tris-HCI pH 8.0, 0.15 M
sodium chloride, 0.05% Tween-20) overnight at 4'C. The
membrane was probed for 60 min with mouse monoclonal
antibody for p53 (PAb 1801), followed by alkaline phos-
phatase-conjugated goat anti-mouse antibody for a further
30 min. The bands were visualised by alkaline phosphatase
substrate solution [100 mM Tris-HCl pH 9.5, 100 mM sodium
chloride, 5 mm magnesium chloride] in 10 ml including 66 gl
of nitroblue tetrazolium (NBT, 50 mg ml-') and 33 gul of
5-bromo-4-chloro-3-indolyl phosphate (BCIP, 50 mg ml-').
Flow cytometry
For studies ofp53 conformational change, cells were cultured
at a concentration of 2 x I0 ml-' in 5 ml of RPMI-1640
containing 10% FCS including either 10% 5637-CM or
recombinant GM-CSF (200unitsml-') for 24h. Then cells
were harvested and washed with phosphate-buffered saline
(PBS, pH 7.2). The cells were fixed with 70% cold ethanol
for 15 min and then washed with PBS twice. The fixed cells
were incubated for 30 min at room temperature with the
mouse anti-human p53 monoclonal antibodies PAb240 and
PAb 1620 or a non-specific mouse IgG monoclonal antibody
as a negative control. The stained cells were washed twice
with PBS and then incubated with a fluorescein iso-
thiocyanate (FITC)-conjugated rabbit anti-mouse immuno-
globulin for a further 30 min. A total of 105 cells were
analysed using a FACScan flow cytometer (Becton-
Dickinson).
Suspension culture ofAML blasts and determination of
apoptotic cells
Cells were cultured in 1.5 ml of RPMI-1640 containing 10%
FCS at a cell concentration of 2 x 106ml1 in triplicate, in
the presence of antisense or sense p53 oligonucleotides at a
final concentration of S IM. After the cells had been treated
for 24 and 48 h, apoptotic cells were recognised on May-
Grunwald-Giesma-stained cytospins by scoring cells with a
fragmented nucleus and condensed chromatin as previously
described (Arends & Wyllie, 1991).
Assayfor DNAfragmentation
DNA was extracted using a DNA extraction kit (Scotlab,
Strathclyde, UK). Cultured leukaemia cells (2 x 106) were
collected by centrifugation, washed with PBS (pH 7.2) twice,
then lysed for 30min at 37°C with 340 gl of lysis buffer
(400 mM Tris-HCI pH 8.0, 60 mM EDTA, 150 mM sodium
chloride, 1% SDS) and 2.5 gil of 50 ggml
1 RNAse A.
Then 100,sl of SM sodium perchlorate was added and the
solution incubated for 20 min at 37°C, and 20 min at 65°C. A
580,sI volume ofcold chloroform was added and the solution
incubated for 20 min at room temperature. Finally, 45glI of
Nucleon Silica suspension was added and the solution cen-
trifuged at 1,300g for 4 min. The DNA was precipitated by
cold ethanol, and the dried DNA pellet was resuspended in
100 tl1 of TE (100 mM Tris-HCl, 1 mM EDTA, pH 8.0).
DNA fragmentation was assessed by 1% agarose gel electro-
phoresis in TAE (40 mM Tris-acetate, 1 mM EDTA, pH 8.0)
at 80 V for 3.5 h. Each lane was loaded with 15#Lg of DNA.
The separated DNA was visualised under ultraviolet light
after staining with 5 ytg ml-' ethidium bromide. ADNA
(EcoRl and HindlII digest) (Sigma, Dorset, UK) was used as
a DNA marker to estimate the size of DNA fragments.
Statistical methods
Data were analysed by a two-sided unpaired Student t-
test.
Results and Discussion
To study the role of wild-type p53 on the induction of
apoptosis in factor-dependent leukaemia cells, we studied
peripheral blood blast cells from four patients with non-
autocrine growth in a clonogenic assay, as well as the factor-
dependent TF-1 cells. The growth characteristics of these
cells are shown in Table I. Positive expression of p53 was
detected in all of these cells by Western blot with PAb1801,
which recognises both wild-type and mutant p53 (Banks et
al., 1986) (Figure 1). p53 has been demonstrated to exist in
two conformational states: one which exhibits a suppressor
effect and one with a promoter effect on cell proliferation
(Milner, 1991; Ullirich et al., 1992). These two conformations
of wild-type p53 can be recognised by different antibodies:
PAb1620 and PAb240 recognise the suppressor and pro-
moter conformations respectively (Ball et al., 1984; Gannon
et al., 1990; Milner & Medcalf, 1991), and PAb240 also
recognises mutant p53 (Gannon et al., 1990). We have
previously shown that the conformation of p53 in AML
blasts is related to growth factor stimulation and is regulated
by exogenous or autocrine haemopoietic growth factors (Zhu
et al., 1993). Thus, cells with non-autocrine growth when
deprived of growth factor express p53 in both the suppressor
and the promoter conformation. However, following growth
factor stimulation, p53 was found to be only present in the
promoter conformation, which is also the conformation
found in blasts with autocrine growth factor production (Zhu
et al., 1993). These findings were confirmed in this study.
Flow cytometric analysis showed that between 20% and 33%
of blasts with non-autocrine growth expressed p53 in the
suppressor (PAbl620+) conformation when cultured in the
absence of exogenous GM-CSF (Figure 2). However, after
these cells were induced to grow by exogenous GM-CSF,
expression of PAb 1620 was found in less than 5% of cells,
and the expression of PAb240, which recognises the pro-
moter conformation of p53, was increased (Figure 2). These
results suggested to us the possibility that wild-type p53 in
the suppressor conformation (PAb1620+) may be involved in
Table I In vitro growth characteristics of AML blasts studied
No. of colonies/2 x 10J cells
Patient FAB type NCM 5637-CM
AML-1 M2 0 40
AML-2 Ml 0 112
AML-3 Ml 0 61
AML-4 M2 0 134
No. of colonies represents the mean of triplicate cultures.
5637-CM contains GM-CSF, G-CSF and IL-1 (Hoang &
McCulloch, 1985). NCM, No conditioned medium, i.e. cells cultured





Figure 1 Expression of p53 in AML blasts of totally CSF-









the induction of apoptosis in factor-deprived leukaemic
cells.
To study this further, antisense oligonucleotides were used
to analyse the effect of suppression of wild-type p53 in blasts
undergoing apoptosis following growth factor deprivation.
Using antisense p53 oligonucleotides which correspond to the
translation initiation region of the p53 mRNA, a dose-
dependent inhibition of p53 expression in TF-I cells by
antisense p53 oligonucleotides was observed (Figure 3).
Using PAb1801 to detect p53, we found that a concentration
of 5gLM antisense oligonucleotides reduced expression from
75% to 16%, and this concentration of oligonucleotides was
then used for further experiments designed to study the effect
of suppression of p53 expression on apoptosis. As also
shown in Figure 3, control sense oligonucleotides had no
effect on p53 expression.
Following growth factor deprivation for 24 h, the percent-
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Figure 2 Conformational change of p53 protein in AML cells
following growth factor stimulation. p53 expression was analysed
by flow cytometry using PAb240 and PAb 1620. AML cells were
cultured without added growth factor (NCM, *) and in the
presence of 5637-conditioned medium (5637-CM) containing
GM-CSF, G-CSF and IL-I (Hoang & McCulloch, 1985) (0).
TF-I cells were cultured both in NCM (M) and in the presence of
recombinant GM-CSF (0). Only AML cells cultured under con-
ditions ofgrowth factor deprivation express p53 in the suppressor
(PAb 1620+) confirmation.
Figure 3 Demonstration of dose-dependent of inhibition of p53
expression in TF-l cells by antisense p53 oligonucleotides. TF-1
cells were treated by varying concentrations ofantisense (- *-)
or sense (-*-) p53 oligonucleotides for 24 h. Expression of
p53 protein was investigated by flow cytometry with the mono-
clonal anti-p53 antibody PAb1801, which recognised both wild-
type and mutant p53. Each point represents the mean ± s.d. of
triplicate cultures.
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Figure 4 DNA fragmentation induced by growth factor depriva-
tion in AML blasts and its suppression by antisense (a) p53
oligonucleotides. Sense (s) p53 ohigonucleotides were used as a
control.
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Table II Apoptosis of factor-dependent AML cells is inhibited by antisense p53
oligononucleotides
Cells with apoptotic nucleus (%)
24h 48h p-value
Source of cells Antisense p53 Sense p53 Antisense p53 Sense p53 (48 h)
TF-1 0.6 0.6 14.3 2.5 10.6 ± 1.0 53.6 ± 3.5 <0.005
AML-1 1.3 1.1 11.3 1.1 10.3 ± 2.3 38.0 ± 2.0 <0.001
AML-2 0.6 ± 0.6 9.3 ± 1.5 5.6 ± 2.0 26.7 ± 3.5 <0.005
AML-3 1.0 ± 1.0 16.0 ± 3.6 3.3 ± 0.5 20.6 ± 2.5 <0.01
AML-4 1.0 1.0 11.0 2.0 5.6 0.5 24.6 ± 3.8 <0.02
TF-I and AML blast cells were treated with antisense or sense p53 oligonucleotides at a final
concentration of 5gM for 24 and 48 h. Apoptotic cells were recognised on May-Grunwald-Giesma-
stained cytospins by scoring cells with a fragmented nucleus and condensed chromation. Each data
point represents the mean ± s.d. of triplicate cultures. Data were statistically analysed by unpaired
Student t-test with two-sided significance level.
apoptosis was between 9.3% and 16.0%, increasing to
between 20.6% and 53.6% at 48 h (Table II). DNA extracted
from these cells showed a characteristic 'DNA ladder' which
is a feature of internucleosomal degradation of DNA (Figure
4). In the presence of 5jM antisense oligonucleotides, apop-
tosis in all samples was inhibited, with <1.5% of cells show-
ing morphological features of apoptosis at 24 h and a similar
degree of suppression at 48 h. These results were confirmed
by the absence of a DNA 'ladder' in DNA extracted from
cells incubated with antisense oligonucleotides (Figure 4).
These results suggested that apoptosis in growth factor-
dependent leukaemic cells is mediated via wild-type p53;
however, suppression ofapoptotic cell death in these cells did
not induce DNA synthesis. As shown in Figure 5, the addi-
tion ofantisense oligonucleotides to cultures of TF-I cells did
not increase DNA synthesis when the cells were cultured
without added GM-CSF.
The data presented here suggest a role for wild-type p53 in
inducing apoptosis in leukaemic cells deprived of growth
factors; indeed, a similar mechanism may operate in normal
haemopoietic progenitors deprived of growth factors as these
cells have been shown to express p53. Recently, p53 has been
implicated in the induction of apoptosis by irradiation and
chemotherapeutic drugs (Clarke et al., 1993; Lowe et al.,
1993). Thus, p53-deficient cells were markedly resistant to the
effects of these agents in inducing apoptosis. Our data would
suggest that wild-type p53 is also involved in apoptosis
occurring in leukaemic cells as the result of growth factor
deprivation, as suppression of p53 protein expression
prevented the onset of apoptosis in these cells. Moreover our
data suggest that this effect is specifically associated with
expression of p53 in the suppressor (PAbl620+) conforma-
tion. These findings also explain why AML cells with auto-
crine GM-CSF production, which only express p53 in the
promoter (PAb240+) conformation (Zhu et al., 1993), do not
undergo apoptosis following in vitro culture. From these
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Figure 5 Effect of antisense oligonucleotides to p53 on DNA
synthesis in TF-1 cells under different culture conditions: (1) no
added growth factors (NCM), (2) 5gM antisense p53 oligonuc-
leotides, (3) 5gm sense p53 oligonucelotides and (4) rGM-CSF
(200 units ml- 1). All experiments were performed in triplicate.
Antisense oligonucleotides to p53 suppressed apoptosis following
association with growth factor deprivation but did not induce cell
proliferation.
(PAb 1620+) of wild-type p53 during leukaemogenesis occurr-
ing either as the result ofmutation or more frequently by the
action of autocrine growth factors, would promote the sur-
vival of cells deprived of exogenous growth factors. Such a
mechanism may be important in permitting the survival and
regrowth of the leukaemic cells following chemotherapy.
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